Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
Justice for hire? Opportunities and challenges in third-party litigation funding in competition collective actions
In many jurisdictions, collective actions in competition law have become an important route for consumers and businesses to seek redress. Yet these cases are costly and complex. Third-party litigation funding (TPLF) has emerged as a central mechanism for making them viable. Recent UK experience provides important lessons on the opportunities… Read More
Podcasts
Should pensions be a source of funding for a country’s investment needs?
The UK government aims to stimulate economic growth by encouraging more investment in British businesses. One potential source of that investment is pension funds, but would such policies truly serve the long-term interests of savers and/or the short-term needs of the economy? In this episode of Top of the Agenda, Dr… Read More